BioMed Innovation

29/06/2024

Key Responsibilities in Medical Equipment Planning
Needs Assessment:

Collaborate with healthcare professionals to determine the types and quantities of medical equipment required.
Assess the clinical and operational needs to ensure the equipment will meet the demands of the healthcare facility.
Selection and Procurement:

Research and evaluate different types of medical equipment based on functionality, reliability, and cost.
Develop specifications for equipment and initiate the procurement process.
Negotiate with vendors and manage contracts to secure the best terms and warranties.
Installation and Commissioning:

Plan the layout and installation of equipment to ensure it fits within the designated space and complies with safety standards.
Oversee the installation process, ensuring that equipment is properly set up and tested for functionality.
Train staff on the proper use and maintenance of the equipment.
Regulatory Compliance:

Ensure all equipment complies with local and international regulations and standards.
Maintain documentation for inspections and audits.
Lifecycle Management:

Monitor the performance and condition of equipment.
Plan for regular maintenance, repairs, and eventual replacement of outdated or faulty equipment.
Manage the disposal of decommissioned equipment in an environmentally responsible manner.

14/10/2021

“Cardiohelp drives a blood pump which takes on the role of the heart’s pump function while an oxygenator works as an artificial lung.

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

07/12/2020

CT scanning used to prolong lives of dolphins kept at Oita aquarium
OITA--Jiji’s four-hour trip aboard a 10-ton truck from here took her to an examination table where she was sedated but continued squeaking.
http://www.asahi.com/sp/ajw/articles/1393264

OITA--Jiji’s four-hour trip aboard a 10-ton truck from here took her to an examination table where

05/11/2020

Scientists develop new photonic sensors to detect SARS-CoV-2

A multidisciplinary team of scientists from the University of Malaga, Spain, is developing a point-of-care system based on photonic sensors to detect SARS-CoV-2.

Led by Robert Halir, a researcher at the Higher Technical School of Telecommunications Engineering, the team has developed a prototype of the sensing system based on photonic chips, and a measuring device, which can detect SARS-CoV-2 proteins in very low concentrations. The prototype has been developed over the past four years and was originally developed to detect antibody biomarkers present in patients that are allergic to antibiotics.

Halir said: “PCR techniques currently applied to detect the virus are reliable, but also slow and expensive, while serological assays, though simpler, lack precision and cannot provide quantitative results.”

Halir explained that their system will precisely add functionality and, in the future, could offer real-time results at a lower cost. The team has been funded with €95,000 under the COVID-19 Fund of the Government of Andalusia to work, for one year, towards demonstrating the system’s ability to detect SARS-CoV-2.

This funding will also allow the team to make changes to the technology in order to reduce its price. Halir said: “If results are satisfactory, in the future we will be able to develop a completely functional point-of-care equipment to be deployed in primary healthcare centres.”

According to the research team, cost reduction would be significant compared to PCR testing, because these tests could be performed directly by family doctors, thus saving the costs of specialised laboratories. The photonic sensors can detect SARS-CoV-2 in less than an hour, significantly reducing the current wait time of COVID-19 tests.

Additional advantages of these sensors include: the ability to detect lower concentrations of antibodies and the technology can also identify the exact number of antibodies a tested person has. “If we succeed, we believe that a commercial prototype could be developed in the near future”, says Halir.

Health Innovation
21st October 2020
Published in :INNOVATION NEWS N E T W O R K

13/10/2018

Diagnosing Sinusitis

ULTRAMAX SINUSULTRA
Made: ENT LAB, FINLAND
The examination method is shown to be effective and accurate by numerous scientific studies
Half of clinically diagnosed sinusitis prove to be wrong in ultrasound examination; thus using an ultrasound device when suspecting sinusitis significantly decreases needless antibiotic treatments. Ultramax devices have a reliability of 80-90% in comparison to irrigation
The device turns on and is ready for examination in a matter of seconds. The examination itself takes little time because no time consuming preparations with the patient are necessary. Average examination time per sinus is 15-45 seconds.

https://www.youtube.com/watch?v=pEhib8fm_vY

10/10/2018

Wristband to Stop Nausea

Last April, the Food and Drug Administration (FDA) approved WAT Medical‘s leading product to treat nausea-induced vomiting: the EmeTerm. Being medication-free, this wristband doesn’t have any of the typical drug side effects like dizziness, drowsiness or thickening of lung secretions, for example.

Presented at FIME 2018, the EmeTerm is based purely on clinically proven neuro modulation technology: it sends an electric current to the nerve system via the P6 acupuncture point on the underside of the wrist; and the electric pulses are then delivered to the brain to precisely block the signal to the stomach which would induce nausea and vomiting.

The EmeTerm can be used in a wide range of treatments including all types of motion sickness caused for example by travelling, pregnancy sickness or chemotherapy treatments. The device has five levels of intensity and a patented electrode design that enhances the transfer of electric pulses from the device to skin.

The wristband is completely dust-proof and water-resistant, and its band is made of hypo-allergenic material. The EmeTerm features magnetic charging lasting up to nine hours. No conduct gel is needed. Designed in Canada and assembled in China, it won the 2017 iF Design Award for its innovative design and usability and is currently used by consumers in over 20 countries worldwide.

01/07/2018

Cordless Small Bone Power System
The NEW Hall® MicroFree™

Features and Benefits

Designed with Comfort in Mind
Cordless Design: Eliminates the inconvenience of cords and awkward hand positioning, allowing for improved maneuverability.
Ergonomic: These well-balanced ergonomic handpieces are designed to feel and work comfortably in surgeons’ hands.1
Precision: Hall MicroFree handpieces come in a surgeon-preferred pencil grip design which helps provide precise cutting.
Safety
Less Risk of Infection: May reduce the potential risk contributing to SSIs, caused by unsecured power cords compromising the sterile field.
Facility Efficiency
Backward Compatibility: Ensures compatibility with highspeed handpiece attachments across all generations of Hall, eliminating the need for costly upgrades.
Optimize Your SPD: Hall MicroFree’s UL- approved batteries are autoclavable. This means they can be placed in the same tray as the handpieces and attachments.
Less Waste: Autoclavable batteries eliminate the need for "blue wrap"
System includes
5 handpieces
1 Mini-Driver™
MicroFree™Power Unit
Small Lithium Battery
2 Sterilization Trays

28/06/2018

Ibis Medical Equipment & Systems
The I Rex Duo (patent pending) is the world's first phototherapy unit to provide 360° coverage in a single LED phototherapy device..

21/06/2018

e Dot Watch is the first Braille smart watch for visually impaired people. The device gives blind users fast, mobile access to information. It is lighter than previous Braille readers, terminals and books, and is claimed to be much cheaper.

The watch can be connected to the user’s smartphone via Bluetooth. Its surface consists of four touch-sensitive dynamic Braille cells. Each has small pins, which descend and rise on the watch’s surface to form Braille letters when a message comes in.

The user can read the messages with the fingers. Dot also functions as a normal watch, offers a slim design and can be worn easily on the wrist.

07/06/2018

Monarch is a new platform from surgical robot pioneer Frederic Moll.
Auris revealed the Monarch Platform, which swaps the da Vinci’s surgical approach for something far less invasive. The system utilizes the common endoscopy procedure to a insert
a flexible robot into hard to reach places inside the human body. A doctor trained on the system uses a video game-style controller to navigate inside, with help from 3D models.
Monarch’s first target is lung cancer, the which tops the list of deadliest cancers. More deaths could be stopped, if doctors were able to catch the disease in its early stages, but the lung’s complex structures, combined with current techniques, make the process difficult. According to the company, “More than 90-percent of people diagnosed with lung cancer do not survive, in part because it is often found at an advanced stage.”

06/06/2018

PENTAX Medical Announces U.S. Deal To Distribute Third Eye® Panoramic™ Imaging System For Colon Cancer Screening..

Avantis Third Eye® Panoramic™ device, a wide-angle visualization tool that significantly expands the view obtained from traditional colonoscopes during screenings for colon cancer.
"The Third Eye Panoramic device uses advanced optics, imaging, and software analysis to better enable diagnosis and early detection of colon cancer with current PENTAX Medical scopes without compromising the high-definition image quality and superior handling characteristics that endoscopists have come to expect from us," said David Woods, President and CEO, PENTAX Medical, Americas. "We continue to innovate and bring new solutions to the market that improve clinical outcomes, enhance the patient and provider experience, and reduce overall costs. This is the latest example of our commitment to enabling our customers to meet their Triple Aim objectives."

According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer in both men and women,3 and that people should be screened for the disease with a colonoscopy once every 10 years, beginning at age 50.4 Colon cancer is expected to cause about 50,630 deaths in 2018.5

"We are very pleased to be partnering with PENTAX Medical to bring our industry-leading and lifesaving solutions to the broader U.S. market," said Tony DiTonno, Chairman of Avantis Medical Systems, Inc. "We evaluated many options for distribution in the U.S., and PENTAX Medical was our overwhelmingly positive first choice."

About PENTAX Medical
PENTAX Medical is a division of Hoya Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopy, informatics, speech, voice, and swallowing assessment products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe. PENTAX Medical employees represent the diverse countries where we do business, allowing us to provide innovative solutions tailored to meet local needs. For more information, visit www.pentaxmedical.com.

About Avantis Medical
For over a decade, Avantis Medical Systems has been a leader in cancer screening and detection. The company has developed an imaging platform technology – utilizing advanced optics, imaging, and software analysis – for the screening and early detection of cancer, with colon cancer as its first clinical application. The company's Third Eye Panoramic device has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) and is now commercially available in the U.S. For more information, visit www.avantismedicalsystems.com.

1 Pickhardt PJ, Nugent PA, Mysliwiec PA, et al. Location of adenomas missed by optical colonoscopy. Ann Intern Med 2004;141:352-9.
2 Siersema PD, Rastogi A, DeMarco DC, et al. Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup. World J Gastroenterol 2012;18:3400-8.
3 https://www.cancer.org/research/cancer-facts-statistics/colorectal-cancer-facts-figures.html
4 https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html
5 https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html

SOURCE PENTAX Medical Company

Related Links
http://www.pentaxmedical.com

17/05/2018

ARveo Microscope : Leica Microsystems, Germany

The ARveo augmented reality microscope with integrated GLOW800 AR fluorescence

A single vision for the future

Cutting edge view of ARveo digital augmented reality microscope marks a new generation of integrated rich information instruments

Wetzlar, Germany. Leica Microsystems launches the ARveo digital augmented reality microscope at the Annual Scientific Meeting 2018 of the American Association of Neurological Surgeons (AANS). The ARveo is a highly advanced neurosurgical microscope with integrated digital augmented reality imaging including groundbreaking GLOW AR technology. GLOW AR technology combines white light and fluorescence into a single, precise view of the surgical site. The ARveo also provides flexible viewing options such as image injection and 3D, as well as wireless sharing beyond the OR. With this comprehensive visualization solution, surgeons have more information to support critical intra-surgical decisions.

“Maximum visual information about cerebral anatomy and physiological processes – this is what neurosurgeons have told us they need most when performing life-changing neurosurgical interventions” says Markus Lusser, President of Leica Microsystems. “ARveo with integrated GLOW AR takes surgical visualization to the next level by placing the latest digital imaging technology at the service of medical progress in the best possible way. The augmented visual information empowers decision-making and supports optimal patient outcomes.”

The ARveo microscope can be supplied with built-in GLOW800* AR fluorescence, the first modality to be powered by groundbreaking GLOW AR technology. GLOW800 takes the high contrast of the ICG fluorescence signal and combines with the white light image to provide a single view of cerebral anatomy in natural color augmented by real-time vascular flow. As GLOW AR technology is future-ready, hospitals can stay at the cutting edge by upgrading as soon as the next modality is launched.